详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. [2]Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. [3]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

关键词： oncolytic viruses cancer therapy recurrent gliomas oncolytic herpes simplex virus adenovirus therapy

摘要：

Recurrent glioma treatment is challenging due to molecular heterogeneity and treatment resistance commonly observed in these tumors. Researchers are actively pursuing new therapeutic strategies. Oncolytic viruses have emerged as a promising option. Oncolytic viruses selectively replicate within tumor cells, destroying them and stimulating the immune system for an enhanced anticancer response. Among Oncolytic viruses investigated for recurrent gliomas, oncolytic herpes simplex virus and oncolytic adenovirus show notable potential. Genetic modifications play a crucial role in optimizing their therapeutic efficacy. Different generations of replicative conditioned oncolytic human adenovirus and oncolytic HSV have been developed, incorporating specific modifications to enhance tumor selectivity, replication efficiency, and immune activation. This review article summarizes these genetic modifications, offering insights into the underlying mechanisms of Oncolytic viruses' therapy. It also aims to identify strategies for further enhancing the therapeutic benefits of Oncolytic viruses. However, it is important to acknowledge that additional research and clinical trials are necessary to establish the safety, efficacy, and optimal utilization of Oncolytic viruses in treating recurrent glioblastoma.Copyright © 2023 Hu, Liao, Tao and Chen.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

第一作者：

第一作者机构： [1]Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. [2]Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [1]Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. [3]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Corrigendum: Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma [2]An oncolytic herpes simplex virus vector, G47 Delta, synergizes with paclitaxel in the treatment of breast cancer [3]The oncolytic herpes simplex virus vector G47 Delta effectively targets breast cancer stem cells [4]Treatment of breast cancer stem cells with oncolytic herpes simplex virus [5]Oncolytic Herpes Simplex Virus Vector G47 Delta Effectively Targets Breast Cancer Stem Cells [6]转基因溶瘤性单纯疱疹病毒对人类乳腺癌细胞及其干细胞的溶瘤作用 [7]The investigation of oncolytic viruses in the field of cancer therapy [8]Clinical and Pathologic Features and Prognostic Factors for Recurrent Gliomas. [9]Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer [10]Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series